首页> 外文会议>International Symposium on the Frontiers of Biotechnology and Bioengineering >Clinical Effect Analysis of Danhong Injection in Treating Apoplexy Cardiovascular and Cerebrovascular Diseases
【24h】

Clinical Effect Analysis of Danhong Injection in Treating Apoplexy Cardiovascular and Cerebrovascular Diseases

机译:丹红注射治疗中风心血管和脑血管疾病的临床疗效分析

获取原文

摘要

Objective: To investigate the effect of Danhong injection in the treatment of apoplexy cardiovascular and cerebrovascular disease. Methods: A total of 132 patients with apoplexy cardiovascular and cerebrovascular disease who were treated in our hospital from January 2016 to October 2018 were randomized. Patients in the control group were given routine treatment. Patients in the experimental group were treated with Danhong injection. The differences in the effects, clinical indicators, stroke scores, CSS scores, ADL score were compared. Results: The total effective rate of the experimental group was 96.97%, which was significantly higher than that of the control group (P<0.05). The plasma specific viscosity (1.85±0.21), whole blood specific viscosity (52.39±6.42), platelet aggregation (4.20±0.51) and volume of red blood cells (49.34±2.13) were significantly improved compared with the control group (P<0.05). The scores of stroke group (1.32±0.25), CSS scores (4.15±1.62) and ADL scores (85.21±10.46) in the experimental group were significantly improved compared with the control group (P<0.05). Conclusion: The application of Danhong injection in patients with apoplexy cardiovascular and cerebrovascular disease can improve the therapeutic effect, improve clinical indicators and scores, and have high safety and promote rehabilitation of patients. It is worthy of popularization and application.
机译:目的:探讨丹虹注射治疗中风心血管和脑血管病治疗的影响。方法:2016年1月至2018年1月在我们院内治疗的患有132例患有的中风心血管和脑血管病患者随机分组。对照组患者进行常规治疗。实验组患者用丹钟注射治疗。比较了效果,临床指标,卒中评分,CSS分数,ADL得分的差异。结果:实验组的总有效率为96.97%,显着高于对照组(P <0.05)。与对照组相比,血浆特异性粘度(1.85±0.21),全血特异性粘度(52.39±6.42),血小板聚集(4.20±0.51)和红细胞体积(49.34±2.13)显着改善(P <0.05 )。与对照组相比,实验组中卒中组(1.32±0.25),CSS分数(4.15±1.62)和ADL评分(85.21±10.46)的分数(P <0.05)明显改善。结论:丹虹注射液在患有中风心血管和脑血管疾病患者中的应用可以提高治疗效果,改善临床指标和分数,具有高安全性和促进患者的康复。它值得普及和应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号